Patient perspectives on DMARD safety concerns in rheumatology trials: Results from inflammatory arthritis patient focus groups and OMERACT attendees discussion

Kathleen M. Andersen; Ayano Kelly; Anne Lyddiatt; Clifton O. Bingham; Vivian P. Bykerk; Adena Batterman; Joan Westreich; Michelle K. Jones; Marita Cross; Peter M. Brooks; Lyn March; Beverley Shea; Peter Tugwell; Lee S. Simon; Robin Christensen; Susan J. Bartlett

doi:10.3899/jrheum.181185

Patient perspectives on DMARD safety concerns in rheumatology trials: Results from inflammatory arthritis patient focus groups and OMERACT attendees discussion

Kathleen M. Andersen, Ayano Kelly, Anne Lyddiatt, Clifton O. Bingham, Vivian P. Bykerk, Adena Batterman, Joan Westreich, Michelle K. Jones, Marita Cross, Peter M. Brooks, Lyn March, Beverley Shea, Peter Tugwell, Lee S. Simon, Robin Christensen, Susan J. Bartlett^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Objective. The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease. Methods. International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees. Results. Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence. Conclusion. Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.

Original language	English
Pages (from-to)	1168-1172
Number of pages	5
Journal	Journal of Rheumatology
Volume	46
Issue number	9
DOIs	https://doi.org/10.3899/jrheum.181185
Publication status	Published - 1 Sept 2019

Access to Document

10.3899/jrheum.181185

Cite this

Andersen, K. M., Kelly, A., Lyddiatt, A., Bingham, C. O., Bykerk, V. P., Batterman, A., Westreich, J., Jones, M. K., Cross, M., Brooks, P. M., March, L., Shea, B., Tugwell, P., Simon, L. S., Christensen, R., & Bartlett, S. J. (2019). Patient perspectives on DMARD safety concerns in rheumatology trials: Results from inflammatory arthritis patient focus groups and OMERACT attendees discussion. Journal of Rheumatology, 46(9), 1168-1172. https://doi.org/10.3899/jrheum.181185

@article{6489be25e0024a109e4906a449482b56,

title = "Patient perspectives on DMARD safety concerns in rheumatology trials: Results from inflammatory arthritis patient focus groups and OMERACT attendees discussion",

abstract = "Objective. The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease. Methods. International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees. Results. Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence. Conclusion. Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.",

keywords = "Clinical trials, Disease-modifying antirheumatic drugs, Drug toxicity, OMERACT, Patient satisfaction, Risk",

author = "Andersen, {Kathleen M.} and Ayano Kelly and Anne Lyddiatt and Bingham, {Clifton O.} and Bykerk, {Vivian P.} and Adena Batterman and Joan Westreich and Jones, {Michelle K.} and Marita Cross and Brooks, {Peter M.} and Lyn March and Beverley Shea and Peter Tugwell and Simon, {Lee S.} and Robin Christensen and Bartlett, {Susan J.}",

year = "2019",

month = sep,

day = "1",

doi = "10.3899/jrheum.181185",

language = "English",

volume = "46",

pages = "1168--1172",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "9",

}

Andersen, KM, Kelly, A, Lyddiatt, A, Bingham, CO, Bykerk, VP, Batterman, A, Westreich, J, Jones, MK, Cross, M, Brooks, PM, March, L, Shea, B, Tugwell, P, Simon, LS, Christensen, R & Bartlett, SJ 2019, 'Patient perspectives on DMARD safety concerns in rheumatology trials: Results from inflammatory arthritis patient focus groups and OMERACT attendees discussion', Journal of Rheumatology, vol. 46, no. 9, pp. 1168-1172. https://doi.org/10.3899/jrheum.181185

TY - JOUR

T1 - Patient perspectives on DMARD safety concerns in rheumatology trials

T2 - Results from inflammatory arthritis patient focus groups and OMERACT attendees discussion

AU - Andersen, Kathleen M.

AU - Kelly, Ayano

AU - Lyddiatt, Anne

AU - Bingham, Clifton O.

AU - Bykerk, Vivian P.

AU - Batterman, Adena

AU - Westreich, Joan

AU - Jones, Michelle K.

AU - Cross, Marita

AU - Brooks, Peter M.

AU - March, Lyn

AU - Shea, Beverley

AU - Tugwell, Peter

AU - Simon, Lee S.

AU - Christensen, Robin

AU - Bartlett, Susan J.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objective. The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease. Methods. International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees. Results. Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence. Conclusion. Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.

AB - Objective. The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease. Methods. International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees. Results. Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence. Conclusion. Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.

KW - Clinical trials

KW - Disease-modifying antirheumatic drugs

KW - Drug toxicity

KW - OMERACT

KW - Patient satisfaction

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=85070241528&partnerID=8YFLogxK

U2 - 10.3899/jrheum.181185

DO - 10.3899/jrheum.181185

M3 - Article

SN - 0315-162X

VL - 46

SP - 1168

EP - 1172

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 9

ER -

Patient perspectives on DMARD safety concerns in rheumatology trials: Results from inflammatory arthritis patient focus groups and OMERACT attendees discussion

Abstract

Access to Document

Other files and links

Fingerprint

Cite this